Other substances

Olmesartan

An angiotensin II receptor antagonist.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
4
 AI-suggested references
0
 Clinical trials

General information

Olmesartan is a synthetic imidazole angiotensin II receptor antagonist (NCIt). It is used for treatment of Type II Diabetes-associated nephropathy. It has been shown to have cardioprotective activity (DrugBank).

Olmesartan on PubChem
Olmesartan on Wikipedia

Marketed as

BENICAR; ERASTAPEX; GOLME; OLMESARTAN; OLMETEC; OLMY; OLSAR; OLVANCE; WINBP

 

Structure image - Olmesartan

CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)O)C(C)(C)O

Supporting references

Link Tested on Impact factor Notes Publication date
Molecular docking, molecular dynamics, and in vitro studies reveal the potential of angiotensin II receptor blockers to inhibit the COVID-19 main protease
3CLpro Small molecule In vitro In silico 		in silico; Vero E6 cells

Showed low free energy in a molecular docking in silico analysis with SARS-CoV-2 3C-like protease (high affinity). Despite seemingly lower stability within molecular dynamics simulation of the interaction, olmesartan displayed potent anti-SARS-CoV-2 activity in Vero E6 cells with high selectivity index (308.4).

 Dec/03/2020

AI-suggested references

Link Publication date
Molecular modeling of the interaction of ligands with ACE2-SARS-CoV-2 spike protein complex
Oct/07/2021
ACE2 as a potential therapeutic target for pandemic COVID-19
Nov/01/2020
Characterization of ACE Inhibitors and AT1R Antagonists with Regard to Their Effect on ACE2 Expression and Infection with SARS-CoV-2 Using a Caco-2 Cell Model
Aug/10/2021
Tissue-specific expression of the SARS-CoV-2 receptor, angiotensin-converting enzyme 2, in mouse models of chronic kidney disease
Aug/19/2021
Export (.csv)